lymphocytic lymphoma


Also found in: Encyclopedia.

lymphocytic lymphoma

Non-Hodgkin's lymphoma, see there.
References in periodicals archive ?
Copiktra was approved in September 2018 by the US Food and Drug Administration for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after at least two prior therapies.
2018 for relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies.
The US FDA approved COPIKTRA in 2018 for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after at least two prior therapies as well as adult patients with relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies.
BeiGene announced results from an ongoing Phase 1b clinical study of its investigational BTK inhibitor zanubrutinib in combination with Gazyva in patients with relapsed/refractory or treatment naive chronic lymphocytic leukemia or small lymphocytic lymphoma, and patients with R/R follicular lymphoma.
Food and Drug Administration (FDA) approved the combination on May 15, 2019, under the FDA's Real-Time Oncology Review and Assessment Aid pilot programs, for the treatment of people with previously untreated CLL or small lymphocytic lymphoma. This is the second regimen of Genentech medicines approved under the RTOR pilot program, which is exploring a more efficient review process to ensure safe and effective treatments are available to patients as early as possible.
Venclexta in combination with Rituxan (rituximab) has been approved by the US Food and Drug Administration (FDA) for the treatment of people with CLL or small lymphocytic lymphoma, with or without 17p deletion, who have received at least one prior therapy.
(3) Reported primary lymphomas include chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), follicular lymphoma, and extranodal marginal zone lymphoma.
Catalent's partner, Verastem Oncology, received approval from the FDA for COPIKTRA (duvelisib) capsules, an oral inhibitor of phosphoinositide 3-kinase (PI3K), for the treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after at least two prior therapies.
10, 2018 (HealthDay News) -- For patients with relapsed or refractory (RR) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), the oral, dual inhibitor of phosphoinositide 3-kinase-?
IDC breast Stage II B with Small lymphocytic lymphoma and chronic lymphocytic leukaemia.
These products require intrathecal administration (into the cerebrospinal fluid) for the prevention or treatment of meningeal leukaemia or lymphocytic lymphoma. About Elliotts B Solution
Mu HCD is the least common of the HCDs and has features resembling chronic lymphocytic leukemia/small lymphocytic lymphoma. Histopathological examination of affected tissues and laboratory evaluation showing heavy chain with no corresponding light chain in the serum or urine is essential to establish the diagnosis of HCD.

Full browser ?